ArticleScientific reports2026
Stimuli-responsive chitosan-coated ferrite nanocarriers for targeted capsaicin delivery and core-dependent HepG2-selective bioactivity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Capsaicin is a promising anticancer agent, but its clinical translation is hindered by poor aqueous solubility, low bioavailability, rapid clearance, and dose-limiting irritation, which restrict sustained exposure at tumor sites. Existing formulations only partially overcome these limitations and often lack tumor-microenvironment–responsive release or a clear understanding of how carrier composition modulates biological outcomes. Here, chitosan-coated zinc ferrite (ZFO@CS) and manganese ferrite (MFO@CS) nanocarriers were developed as pH- and glutathione-responsive platforms for capsaicin delivery. The nanocarriers exhibited nanoscale hydrodynamic diameters (~ 120–500 nm) and highly positive zeta potentials (+ 30 to + 50 mV), enabling high encapsulation efficiencies (up to ~ 88%) and colloidal stability. Under physiological pH 7.4, less than 10% of the loaded drug was released over 48 h, whereas ~ 30–40% was liberated under acidic, glutathione-rich conditions mimicking the tumor microenvironment, indicating dual stimulus-triggered behavior. Encapsulation improved capsaicin’s selective cytotoxicity toward HepG2 liver cancer cells, with CAP-MFO@CS achieving a higher therapeutic index than free capsaicin, while maintaining acceptable compatibility with normal WI-38 fibroblasts. The nanocarriers also enhanced antibacterial and antioxidant activities. DNA binding and stopped-flow kinetics revealed that ferrite core composition modulates binding affinity and kinetic stability of DNA–nanocomposite complexes, providing a mechanistic link between material properties and bioactivity. These findings demonstrate that core-dependent design of ferrite–chitosan nanocarriers can improve capsaicin bioavailability, selectivity, and multifunctional therapeutic performance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.